Published in Cancer Weekly, May 4th, 2004
Sales for Avastin (bevacizumab) were $38.1 million in the first quarter of 2004.
Operating revenues increased by 30% from the first quarter of 2003 to $975.1 million.
"Genentech is starting out the year with good quarterly performance, led by strong product sales. We have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.